Semaglutide

CAS No.: 910463-68-2

Semaglutide Chemical Structure

Molecular formula: C₁₈₇H₂₉₁N₄₅O₅₉

Molecular weight: 4113.5775

Patent period: Compound: 2026

Composition: 2029

Dositive specifications: 1.34mg/ml

Injection : 1.5ml, 3.0ml/support

Oral tablets: 3mg, 7 mg, 14 mg, once a day

Injection (weight loss, wegovy):

2.4mg/0.75ml

Biological Activity

Semaglutide causes thyroid C-cell tumors. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of semaglutide-induced rodent thyroid Ccell tumors has not been determined.

There are currently three FDA-approved semaglutide products:

__ Ozempic

__ Rybelsus

__ Wegovy

Chemical Properties

ACTIONS	Agonist
CAS NO.	910463-68-2
FORMULA	C₁₈₇H₂₉₁N₄₅O₅₉
M.WT	4113.64
PURITY	>98%
SYNONYMS	Ozempic Rybelsus Wegvovy
STORAGE	The shelf life of the drug product is 36 months at 5 °C, and the in-use shelf life is 56 days at 5 °C to 30 °C after initial use.

Online Inquiry

Diabetes

Chinese diabetic people may have a total of 143 million people, accounting for 23%of the global patients with diabetes. It is the country with the most diabetic patients in the world. Among them, type II diabetes account for about 90%of the number of diabetes, and type I diabetes and gestational diabetes account for about 9 ~ 10%.

Other Drug Peptide

Terzapitide NEW

Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.

Semaglutide NEW

Semaglutide causes thyroid C-cell tumors. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.

Retatrutide NEW

Retatrutide (LY3437943) is a triple agonist peptide of glucagon receptor (GCGR), glucose-dependent insulin- promoting peptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R), developed for the treatment of obesity and related metabolic disorders.

Cagrilintide NEW

Cagrilintide is an investigational novel long-acting acylated amylin analogue, acting as a nonselective amylin receptor (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake.

Linaclotide NEW

Linaclotide is a potent and selective guanylate cyclase C agonist, developed for the treatment of constipation-type irritable bowel syndrome (IBS-C) and chronic constipation.

BESTBELL